title: Age-specific administration of chemotherapy and long-term quality of life in stage II and III colorectal cancer patients: a population-based prospective cohort.
abstract: OBJECTIVE
  To investigate the age-specific pattern of administration of chemotherapy and its association with long-term survival and quality of life (QoL) in stage II and III colorectal cancer patients.
  
  
  METHODS
  Chemotherapy allocation according to disease and patient characteristics was investigated in a population-based cohort of 562 stage II and III colorectal cancer patients. Five years after diagnosis, survival was determined and QoL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Items and a tumor specific module. The association among chemotherapy, survival, and QoL was examined while controlling for potential confounders.
  
  
  RESULTS
  Chemotherapy was administered in 71% of patients aged <60 years and in only 20% of patients aged ≥80 years. A significant association between chemotherapy and longer survival time was found for stage III cancer only. Chemotherapy was associated with higher symptom levels for trouble with taste, anxiety, and hair loss. In age-specific analyses, younger survivors (<70 years at time of follow-up) with a history of chemotherapy reported significantly lower physical, role, and cognitive functioning and higher pain, appetite loss, hair loss, and trouble with taste symptom levels. In contrast, for older survivors (≥70 years), only two (hair loss and dry mouth) out of 38 QoL scores were significantly associated with chemotherapy.
  
  
  CONCLUSIONS
  Chemotherapy is associated with lower long-term QoL, especially in younger survivors. In cases of uncertain survival benefits of chemotherapy, consideration of its long-term effects on QoL should be incorporated into final decisions on treatment.
authors.affiliation: Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (dkfz), Heidelberg, Germany.
authors.forename: Lina
authors.initials: L
authors.lastname: Jansen
authors.forename: Michael
authors.initials: M
authors.lastname: Hoffmeister
authors.forename: Jenny
authors.initials: J
authors.lastname: Chang-Claude
authors.forename: Moritz
authors.initials: M
authors.lastname: Koch
authors.forename: Hermann
authors.initials: H
authors.lastname: Brenner
authors.forename: Volker
authors.initials: V
authors.lastname: Arndt
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D015331:Cohort Studies; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000503:physiopathology* / Q000523:psychology; D018572:Disease-Free Survival; D005260:Female; D006304:Health Status; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010818:Practice Patterns, Physicians'; D011446:Prospective Studies; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents
references.citation: J Clin Oncol. 1998 Jan;16(1):139-44
references.pmid: 9440735
references.citation: Lancet. 2001 Oct 20;358(9290):1291-304
references.pmid: 11684209
references.citation: J Clin Oncol. 1999 Aug;17(8):2412-8
references.pmid: 10561304
references.citation: Int J Cancer. 2007 Jul 15;121(2):395-400
references.pmid: 17372898
references.citation: Oncologist. 2010;15(6):584-92
references.pmid: 20495217
references.citation: Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
references.pmid: 12900694
references.citation: Eur J Cancer. 2010 Nov;46(16):2879-88
references.pmid: 20605090
references.citation: Cancer. 2010 Jul 15;116(14):3348-56
references.pmid: 20564075
references.citation: Eur J Cancer. 2009 Nov;45(17):3017-26
references.pmid: 19765978
references.citation: J Natl Cancer Inst. 2001 Jun 6;93(11):850-7
references.pmid: 11390534
references.citation: Oncology (Williston Park). 2006 Feb;20(2):135-43; discussion 144, 146, 151-2
references.pmid: 16562648
references.citation: N Engl J Med. 1999 Dec 30;341(27):2061-7
references.pmid: 10615079
references.citation: Clin Pharmacol Ther. 2009 Oct;86(4):416-24
references.pmid: 19606090
references.citation: J Clin Oncol. 2005 Jul 1;23(19):4399-405
references.pmid: 15994149
references.citation: Ann Surg Oncol. 2001 Jan-Feb;8(1):44-9
references.pmid: 11206224
references.citation: Cancer. 2008 Aug 15;113(4):879-86
references.pmid: 18521903
references.citation: Eur J Cancer. 2007 Jul;43(10):1564-73
references.pmid: 17521904
references.citation: Cancer. 1999 Nov 1;86(9):1768-74
references.pmid: 10547550
references.citation: J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
references.pmid: 8433390
references.citation: Z Gastroenterol. 2008 Aug;46(8):799-840
references.pmid: 18759205
references.citation: Cancer. 2008 Dec 15;113(12 Suppl):3519-29
references.pmid: 19058151
references.citation: Lancet. 2007 Dec 15;370(9604):2020-9
references.pmid: 18083404
references.citation: Ann Intern Med. 2011 Jan 4;154(1):22-30
references.pmid: 21200035
references.citation: Oncologist. 2006 Mar;11(3):234-42
references.pmid: 16549807
references.citation: Eur J Cancer. 2005 Nov;41(17):2613-9
references.pmid: 16226458
references.citation: J Clin Oncol. 2004 May 15;22(10):1797-806
references.pmid: 15067028
references.citation: Eur J Cancer. 2006 Aug;42(12):1848-57
references.pmid: 16829069